Loading…
Journey Medical Corporation is projected to rise to $6.90 by 2027, a +15% move from its current price of $5.99. DERM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.81 | $5.99 | $6.18 | +0.03% |
| May 30 | $5.74 | $5.99 | $6.26 | +0.06% |
| May 31 | $5.68 | $6.00 | $6.33 | +0.09% |
| Jun 1 | $5.64 | $6.00 | $6.38 | +0.12% |
| Jun 2 | $5.60 | $6.00 | $6.43 | +0.15% |
| Jun 3 | $5.56 | $6.00 | $6.47 | +0.18% |
| Jun 4 | $5.53 | $6.00 | $6.51 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.53 | $6.00 | $6.51 | +0.21% |
| Week 2 | $5.36 | $6.01 | $6.75 | +0.42% |
| Week 3 | $5.23 | $6.03 | $6.94 | +0.62% |
| Week 4 | $5.13 | $6.04 | $7.11 | +0.83% |
| Week 5 | $5.04 | $6.05 | $7.27 | +1.04% |
| Week 6 | $4.96 | $6.06 | $7.41 | +1.25% |
| Week 7 | $4.89 | $6.08 | $7.55 | +1.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. Its marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
The company was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation was formerly known as Coronado Dermatology, Inc.
Journey Medical Corporation (DERM) is currently trading at $5.96 per share, with a market capitalization of $164.11M. It holds a relatively modest market position with a ranking of 3965. The outlook from the year-by-year forecast shows a bullish path over time, with the 2026 average price at $5.96 and rising to $10.25 by 2030, $21.65 by 2040, and $51.14 by 2050.
The forecast envisions upside in cumulative ROI from 0 in 2026 to 72 in 2030, 263.2 by 2040, and 758.1 by 2050.
A major floor 27.8% below — a decisive break under it would weaken the trend.
The nearest floor, 17.9% below — buyers have tended to step in here.
The nearest ceiling, 6.0% above — a clean break opens room to run.
A major ceiling 54.6% above — clearing it would confirm fresh momentum.
Key DERM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DERM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.09 | Sell | $6.05 | Sell |
| MA 10 | $6.07 | Sell | $5.95 | Buy |
| MA 20 | $5.58 | Buy | $5.75 | Buy |
| MA 50 | $5.53 | Buy | $5.90 | Buy |
| MA 100 | $6.83 | Sell | $6.41 | Sell |
| MA 200 | $7.23 | Sell | $6.74 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.62 | Neutral |
| Stoch RSI (14) | 58.78 | Neutral |
| CCI (20) | 51.38 | Neutral |
| Williams %R (14) | -26.67 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 18.15 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 73.33 | Neutral |
| TRIX (15) | 0.30 | Buy |
| Awesome (5,34) | 0.67 | Buy |
| Ultimate (7,14,28) | 43.42 | Neutral |
| Momentum (10) | 0.98 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 6.02 | Sell |
| ADX (14) | 22.37 | Buy |
| ATR (14) | 0.16 | Info |
The 30-day technical picture is bullish. The RSI14 sits at 60, and the near-term trend is framed by the SMA50 at $5.58 and the SMA200 at $7.24. Near-term support is at $4.92 and resistance at $6.35, with the 30-day price range extending from $4.82 to $7.36. The stock experiences an annualized volatility of 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.39 | $5.99 | $8.24 | 0% | Neutral | |
| $5.41 | $6.90 | $9.38 | +15% | Neutral | |
| $5.07 | $6.68 | $9.44 | +11% | Neutral | |
| $5.80 | $7.85 | $11.45 | +31% | Bullish | |
| $7.15 | $9.89 | $14.82 | +65% | Bullish | |
| $8.03 | $11.36 | $17.41 | +90% | Bullish | |
| $8.40 | $12.12 | $18.97 | +102% | Bullish | |
| $8.45 | $12.43 | $19.81 | +107% | Bullish | |
| $8.81 | $13.19 | $21.40 | +120% | Bullish | |
| $9.01 | $13.73 | $22.63 | +129% | Bullish | |
| $12.53 | $20.65 | $36.39 | +245% | Bullish | |
| $25.11 | $47.56 | $92.33 | +694% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.39 | $5.99 | $7.07 | +0.00% |
| June 2026 | $5.27 | $6.21 | $7.50 | +3.63% |
| July 2026 | $5.18 | $6.15 | $7.55 | -0.86% |
| August 2026 | $5.08 | $6.09 | $7.56 | -1.04% |
| September 2026 | $5.25 | $6.33 | $7.93 | +3.92% |
| October 2026 | $5.37 | $6.51 | $8.23 | +2.91% |
| November 2026 | $5.26 | $6.41 | $8.16 | -1.54% |
| December 2026 | $5.25 | $6.43 | $8.24 | +0.27% |
Click any year to see its month-by-month DERM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, DERM is projected to trade between $4.39 and $8.24, averaging $5.99 — a potential gain of 0% from today's $5.99. A consolidation phase looks the most probable path here.
Journey Medical Corporation's 2027 outlook centres on $6.90, within a $5.41 to $9.38 range. That is up +15% on the projected 2026 average. That marks a +15% change versus current levels. Price action looks broadly range-bound.
By 2028, DERM could reach as high as $9.44, with a base case around $6.68 and support toward $5.07 — roughly +11% from $5.99. A consolidation phase looks the most probable path here.
Expect DERM to range from $5.80 to $11.45 through 2029. The $7.85 average target implies a +31% move from current prices. That is up +18% on the projected 2028 average. Momentum favours further upside here.
The DERM price prediction for 2030 points to an average of $9.89 (low $7.15, high $14.82) — a potential gain of +65% on today's $5.99. Buyers look set to stay in control over this stretch.
In 2031, DERM is projected to trade between $8.03 and $17.41, averaging $11.36 — a potential gain of +90% from today's $5.99. That is up +15% on the projected 2030 average. Momentum favours further upside here.
Journey Medical Corporation's 2032 outlook centres on $12.12, within a $8.40 to $18.97 range. That is up +7% on the projected 2031 average. That marks a +102% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, DERM could reach as high as $19.81, with a base case around $12.43 and support toward $8.45 — roughly +107% from $5.99. Momentum favours further upside here.
Expect DERM to range from $8.81 to $21.40 through 2034. The $13.19 average target implies a +120% move from current prices. That is up +6% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The DERM price prediction for 2035 points to an average of $13.73 (low $9.01, high $22.63) — a potential gain of +129% on today's $5.99. Momentum favours further upside here.
In 2040, DERM is projected to trade between $12.53 and $36.39, averaging $20.65 — a potential gain of +245% from today's $5.99. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Journey Medical Corporation's 2050 outlook centres on $47.56, within a $25.11 to $92.33 range. That is up +130% on the projected 2040 average. That marks a +694% change versus current levels. Momentum favours further upside here.
Investing $1,000 in DERM today (≈ 166.944908 DERM) could be worth
$7,939.55
+$6,939.55 (+694%) by 2050 · US Dollar
Based on the average projected DERM price of $47.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DERMwould be worth at today's price.
$1,000 invested in DERM on May 27, 2025 (≈ 128.700129 DERM) would be worth
$770.91
-$229.09 (-22.9%) today · 0.77× · US Dollar
Based on a DERM entry price of $7.77 vs. today's $5.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.17 | $970.83 | -2.9% |
| 1 month ago | $5.26 | $1,138.78 | +13.9% |
| 3 months ago | $8.71 | $687.72 | -31.2% |
| 6 months ago | $8.07 | $742.26 | -25.8% |
| 1 year ago | $7.77 | $770.91 | -22.9% |
| All time (4.5y) ago | $9.9 | $605.05 | -39.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DERM forecast.
Our base-case forecast reaches $12.00 around 2032.
Implied market cap at $12.00: $258.41M
The multi-year forecast points to a bullish trajectory, with the 2030 average price at $10.25 and a return on investment of 72, and the 2040 average price at $21.65 with ROI of 263.2, followed by the 2050 average price at $51.14 and ROI of 758.1. The 2029 forecast shows an average of $8.06 and ROI 35.3, and the 2031–2035 sequence supports continued upside with 2031 avg $11.65 (ROI 95.4), 2032 avg $12.62 (ROI 111.7), 2033 avg $12.90 (ROI 116.4), 2034 avg $13.61 (ROI 128.3), and 2035 avg $14.43 (ROI 142). These are estimates and not guarantees.
The sentiment remains BULLISH across the longer horizon, but actual results can differ due to market conditions and other factors.
Tap a question to reveal the answer.
2030 avg $10.25; min $7.34; max $15.49; ROI 72; sentiment BULLISH.
The longer-horizon forecast shows rising averages and bullish sentiment from 2026 onward, including 2030 avg $10.25 and 2050 avg $51.14, with ROI reaching 758.1 by 2050. These are estimates and not guarantees.
The 2050 forecast lists an average of $51.14 and a max of $100.84, indicating potential to exceed $50 on the forecast horizon.
Current price is $5.96 and market cap is $164.11M; the rank is 3965.
Sentiment: BULLISH. RSI14: 60. SMA50: $5.58. SMA200: $7.24. 30-day range: $4.82–$7.36. Support: $4.92. Resistance: $6.35. Annualized volatility: 60%.
Journey Medical Corporation Community Discussion
0Share your Journey Medical Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.